Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Carnio S, Novello S, Papotti M, et al. Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures. Transl Lung Cancer Res. 2013;2:372–381. doi:10.3978/j.issn.2218-6751.2013.10.05
   PubMedGoogle Scholar
• Uramoto H, Tanaka F. Recurrence after Surgery in Patients with NSCLC. Transl Lung Cancer Res. 2014;3:242–249. doi:10.3978/j.issn.2218-6751.2013.12.05
   PubMedGoogle Scholar
• Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561–1571. doi:10.1016/S0140-6736(13)62159-5
   PubMed Web of Science ®Google Scholar
• de Miguel M, Calvo E. Clinical Challenges of Immune Checkpoint Inhibitors. Cancer Cell. 2020;38:326–333. doi:10.1016/j.ccell.2020.07.004
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok J. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40:586–597. doi:10.1200/JCO.21.01497
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aggarwal C, et al. NCCN guidelines insights: non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw. 2019;17:1464–1472. doi:10.6004/jnccn.2019.0059
   PubMed Web of Science ®Google Scholar
• Uprety D, Mandrekar SJ, Wigle D, et al. Neoadjuvant Immunotherapy for NSCLC: current Concepts and Future Approaches. J Thorac Oncol. 2020;15:1281–1297. doi:10.1016/j.jtho.2020.05.020
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:eaax0182. doi:10.1126/science.aax0182
   PubMed Web of Science ®Google Scholar
• Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976–1986. doi:10.1056/NEJMoa1716078
   PubMed Web of Science ®Google Scholar
• Eichhorn F, Klotz LV, Kriegsmann M, et al. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience. Lung Cancer. 2021;153:150–157. doi:10.1016/j.lungcan.2021.01.018
   PubMed Web of Science ®Google Scholar
• Wislez M, Mazieres J, Lavole A, et al. Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO). J Immunother Cancer. 2022;10:e005636. doi:10.1136/jitc-2022-005636
   PubMed Web of Science ®Google Scholar
• Gao S, Li N, Gao S, et al. Neoadjuvant PD-1 Inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15:816–826. doi:10.1016/j.jtho.2020.01.017
   PubMed Web of Science ®Google Scholar
• Tong BC, Gu L, Wang X, et al. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022;163:427–436. doi:10.1016/j.jtcvs.2021.02.099
   PubMed Web of Science ®Google Scholar
• Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413–1422. doi:10.1016/S1470-2045(20)30453-8
   PubMed Web of Science ®Google Scholar
• Rothschild SI, Zippelius A, Eboulet EI, et al. Sakk 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial. J Clin Oncol. 2021;39:2872–2880. doi:10.1200/JCO.21.00276
   PubMed Web of Science ®Google Scholar
• Zhao ZR, Yang CP, Chen S, et al. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Oncoimmunology. 2021;10:1996000. doi:10.1080/2162402X.2021.1996000
   PubMed Web of Science ®Google Scholar
• Yang CJ, McSherry F, Mayne NR, et al. Surgical outcomes after neoadjuvant chemotherapy and ipilimumab for non-small cell lung cancer. Ann Thorac Surg. 2018;105:924–929. doi:10.1016/j.athoracsur.2017.09.030
   PubMed Web of Science ®Google Scholar
• Wang J, Li J, Cai L, et al. The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer. Ann Transl Med. 2021;9:486. doi:10.21037/atm-21-670
   PubMed Web of Science ®Google Scholar
• Shu CA, Gainor JF, Awad MM, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:786–795. doi:10.1016/S1470-2045(20)30140-6
   PubMed Web of Science ®Google Scholar
• Tfayli A, Al Assaad M, Fakhri G, et al. Neoadjuvant Chemotherapy and Avelumab in Early Stage Resectable Nonsmall Cell Lung Cancer. Cancer Med. 2020;9:8406–8411. doi:10.1002/cam4.3456
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–1985. doi:10.1056/NEJMoa2202170
   PubMed Web of Science ®Google Scholar
• Reuss JE, Anagnostou V, Cottrell TR, et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020;8:e001282.
   PubMed Web of Science ®Google Scholar
• Chansky K, Detterbeck FC, Nicholson AG, et al. The IASCL lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017;12:1109–1121. doi:10.1016/j.jtho.2017.04.011
   PubMed Web of Science ®Google Scholar
• Travis WD, Dacic S, Wistuba I, et al. IASCL multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol. 2020;15:709–740. doi:10.1016/j.jtho.2020.01.005
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Chaft JE, William WN, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:e42–50. doi:10.1016/S1470-2045(13)70334-6
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301. doi:10.1056/NEJMoa1716948
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. doi:10.1056/NEJMoa1809697
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–2051. doi:10.1056/NEJMoa1810865
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–2092. doi:10.1056/NEJMoa1801005
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med. 2016;35:5642–5655. doi:10.1002/sim.7084
   PubMed Web of Science ®Google Scholar
• Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA Non-small-cell lung cancer. Lung Cancer. 1998;21:1–6. doi:10.1016/S0169-5002(98)00046-4
   PubMed Web of Science ®Google Scholar
• Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg. 2003;125:254–260. doi:10.1067/mtc.2003.15
   PubMed Web of Science ®Google Scholar
• El Kadmiri MAA, Rajan A. Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit? J Thorac Dis. 2018;10:S3203–S6. doi:10.21037/jtd.2018.08.39
   PubMed Web of Science ®Google Scholar
• Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett. 2018;419:210–221. doi:10.1016/j.canlet.2018.01.050
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30:61–69. doi:10.1007/s10555-011-9273-4
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3:436–443. doi:10.1158/2326-6066.CIR-15-0064
   PubMed Web of Science ®Google Scholar
• Pol J, Vacchelli E, Aranda F, et al. Trial watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015;4:e1008866. doi:10.1080/2162402X.2015.1008866
   PubMed Web of Science ®Google Scholar
• Qu Y, Emoto K, Eguchi T, et al. Pathologic assessment after neoadjuvant chemotherapy for NSCLC: importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma. J Thorac Oncol. 2019;14:482–493. doi:10.1016/j.jtho.2018.11.017
   PubMed Web of Science ®Google Scholar
• Mouillet GME, Milleron B, Puyraveau M, et al. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. J Thor Oncol. 2012;7:841–849. doi:10.1097/JTO.0b013e31824c7d92
   PubMed Web of Science ®Google Scholar
• Ulas EB, Dickhoff C, Schneiders FL, et al. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. ESMO Open. 2021;6:100244. doi:10.1016/j.esmoop.2021.100244
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Suntharalingam M, Burrows W, et al. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg. 2008;86:903–910. doi:10.1016/j.athoracsur.2008.06.022
   PubMed Web of Science ®Google Scholar
• Albain KS, Swann RS, Rusch VW, et al. radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–386. doi:10.1016/S0140-6736(09)60737-6
   PubMed Web of Science ®Google Scholar
• Si H, Du D, Li W, et al. Sputum-based tumor fluid biopsy: isolation and high-throughput single-cell analysis of exfoliated tumor cells for lung cancer diagnosis. Anal Chem. 2021;93:10477–10486. doi:10.1021/acs.analchem.1c00833
   PubMed Web of Science ®Google Scholar
• Qiu F, Fan J, Shao M, et al. Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): a randomized, single center, two-arm phase II trial. J Clin Oncol. 2022;40:16. doi:10.1200/JCO.2022.40.16_suppl.8500
   Google Scholar